Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Laboratory science

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background and objectives Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a neurodegenerative condition often overlapping clinically with Alzheimer disease (AD). No established in vivo biomarkers exist for LATE. The amygdalar atrophy scale (AAS) is a visual MRI rating tool scoring the amygdala as AAS 0 (no atrophy), AAS 1 (mild-to-moderate atrophy), or AAS 2 (severe atrophy) and is associated with TDP-43 neuropathology in limbic regions. This study describes the clinical, neuroimaging, and longitudinal cognitive profiles of individuals classified using a proposed framework that combines the AAS with established AD biomarkers. Methods This retrospective study included individuals attending the Geneva Memory Center (2014-2022) who underwent T1-weighted MRI, as well as clinical and neuropsychological assessments. Participants were categorized with an etiologic grouping defined as No-AD/No-LATE (AAS 0 , negative AD biomarkers), AD (AAS 0 , positive AD biomarkers), LATE (AAS 1-2 , negative AD biomarkers), or AD/LATE (AAS 1-2 , positive AD biomarkers). Group differences were compared using Kruskal-Wallis or χ 2 tests. Differences in MRI brain volumes and cortical thickness between groups were examined with analysis of covariance. Cognitive trajectories using Mini-Mental State Examination (MMSE) scores over 30 months were estimated with linear mixed-effects models accounting for baseline age and education. Results The analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female). The No-AD/No-LATE group exhibited the highest MMSE scores (N = 181, 27.9 ± 2.2), outperforming AD (N = 146, 24.2 ± 4.9), LATE (N = 36, 26.2 ± 3.2), and AD/LATE (N = 106, 22.5 ± 5.3) groups ( p p p = 0.813), whereas both AD (β = -0.136, 95% CI -0.184 to -0.088, p p Discussion Patients identified as LATE by the integration of AAS with AD biomarkers had generally mild amnestic cognitive impairment, significant limbic atrophy, and slow decline over time, all features consistent with previous autopsy series. Moreover, AD/LATE cases were more impaired than those with LATE or AD alone. Prospective and neuropathologic validation is warranted.

What this study adds

Evidence grade: Early

This is a follow-up (cohort) study of 469 participants. This study describes a visual MRI rating of amygdala shrinkage used together with existing Alzheimer's biomarkers to sort memory clinic patients into groups, including one thought to have LATE. Reported effect size: MMSE slope over 30 months: -0.010 (LATE) vs -0.136 (AD) and -0.139 (AD/LATE).

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Roveta, F., Pizzini, F. B., Natale, V., Scheffler, M., Garibotto, V., Mendes, A. J., et al. (2026). Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic. Neurology. https://doi.org/10.1212/WNL.0000000000214477

Vancouver

Roveta F, Pizzini FB, Natale V, Scheffler M, Garibotto V, Mendes AJ, et al. Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic. Neurology. 2026. doi:10.1212/WNL.0000000000214477. PMID: 41428981.

BibTeX

@article{roveta2026-41428981,
  author  = {Roveta, F. and Pizzini, F. B. and Natale, V. and Scheffler, M. and Garibotto, V. and Mendes, A. J. and Wang, C. and Lathuiliere, A. and Chicherio, C. and Rainero, I. and Frisoni, G. B. and Ribaldi, F.},
  title   = {{Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic}},
  journal = {Neurology},
  year    = {2026},
  doi     = {10.1212/WNL.0000000000214477},
  pmid    = {41428981},
  url     = {https://doi.org/10.1212/WNL.0000000000214477}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 12 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study describes a visual MRI rating of amygdala shrinkage used together with existing Alzheimer's biomarkers to sort memory clinic patients into groups, including one thought to have LATE. It is a retrospective description of patient profiles, not a treatment or cure, and it does not show that this approach changes outcomes.

Study details

Limitations

Retrospective single-centre design with investigations determined by routine practice, creating selection bias and possibly affecting internal validity; the LATE group was small (n = 36), lowering power; and other causes of amygdalar atrophy such as alpha-synuclein or frontotemporal TDP-43 pathology were not evaluated for lack of biomarkers or autopsy confirmation.

How this study scored 56/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 55 of the 98 points it could be judged on, which is 56 of 100. Total 56 of 100.55 of the 98 points we could judge = 56 of 100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 55 of the 98 points we could judge it on, which is 56 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 469 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 2 year(s) since 2026
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Federica Ribaldi: h-index 25 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Geneva: institution h-index 1,049 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41428981)
Free to read — / 2 Access not recorded — left out of this score
Points 55 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 98 points we could judge it on is 56 out of 100.
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Laboratory science from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Laboratory science

See all studies in Laboratory science →